Is Enfortumab already on the market?

Enfortumab/Enfortumab is an innovative antibody drug mainly used to treat advanced or metastatic urothelial cancer (mUC; bladder cancer). As a new option for targeted immune combination therapy, Enfortumab mediates cytotoxicity by targeting specific antigens on the surface of urothelial cancer cells, thereby effectively inhibiting tumor growth and spread. Its time to market varies in different countries, but it has entered clinical use globally.

In China, veentuzumab was approved for marketing in August 2024 under the trade name Besifu. This approval marks the first time that Chinese patients can obtain this innovative anti-cancer drug through formal channels in the country, providing a new treatment option for patients with locally advanced or metastatic urothelial cancer. In the U.S. market, Enfortumab was approved by the FDA as early as December 2019, with the trade name PADCEV, becoming a new generation of targeted drugs clinically available in the United States. The European Union also officially approved marketing in April 2022, with the trade name Padcev, demonstrating its wide recognition and clinical value in the international market.

The successful launch of Enfortumab not only provides new treatment opportunities for patients, but also provides doctors with targeted drugs that can be selected after the failure of chemotherapy and immunotherapy regimens. In clinical practice, Enfortumab can be used in combination with immune checkpoint inhibitors such as pembrolizumab to improve the therapeutic effect of patients with locally advanced or metastatic urothelial cancer. At the same time, single-agent use also provides a feasible solution for patients who cannot tolerate chemotherapy or immunotherapy.

In general, veentuzumab has been launched in many countries and regions around the world, and has also been approved in the Chinese market in 2024, marking a new clinical stage in the treatment of urothelial cancer. Patients need to evaluate their condition under the guidance of a doctor before use, and choose the most suitable treatment plan based on past treatment history.

Reference: https://www.padcev.com/